journal article·2025-11-10Open access

Energy-Dependent Neutron Emission in Medical Cyclotrons: Differences Between 18F and 11C and Implications for Radiation Protection

Teresa Jakubowska, Michał Biegała

Applied Sciences· Volume 15· Issue 22

Abstract

This study investigates neutron radiation sources in medical cyclotrons used for PET isotope production, focusing on differences between 18F and 11C. Neutron and gamma dose rates were measured in the bunker and operator control room during routine production with an 11 MeV Eclipse cyclotron. 18F production generated approximately 2.5 times higher neutron levels in the bunker than 11C. Shielding performance also varied: the same wall reduced neutron fluxes by factors of kF = 14,000 for 18F and kC = 86,000 for 11C, while gamma shielding was similar for both isotopes (kγ ≈ 28,000). However, the neutron shielding factor calculated from the data for 18F should be taken as kF ≥ 1.4 × 104, because several neutron readings reached the upper limit of the detector range, which indicates a partial underestimation of the dose in the bunker. Consequently, neutron levels in the control room during 18F production were about 15-fold higher than during 11C production. These differences result from distinct neutron generation mechanisms. The 18O(p,n)18F reaction produces primary neutrons with a Maxwellian spectrum (~2.5 MeV), while 11C neutrons arise solely from secondary interactions in structural materials. The findings emphasize the need for composite shielding adapted to isotope-specific spectra. Annual dose estimates (260 18F and 52 11C productions) showed neutron exposure (3.78 mSv/year, 57%) exceeded gamma exposure (2.82 mSv/year, 43%). The total dose of 6.6 mSv/year is ~33% of regulatory limits, supporting compliance but underscoring the need for dedicated neutron dosimetry.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Radiation Therapy and Dosimetry · Boron Compounds in Chemistry · Medical Imaging Techniques and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Medicine, Department of Medical Imaging Technology, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland

Department of Medical Physics, Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology, Pabianicka 62, 93-513 Lodz, Poland

References (28)

Show source-provided references
1. International Atomic Energy Agency (2008). Cyclotron Produced Radionuclides: Principles and Practice, IAEA.
2. International Atomic Energy Agency (2012). Cyclotron Produced Radionuclides: Operation and Maintenance of Gas and Liquid Targets, IAEA.
3. Neutron energy spectra inside a PET cyclotron vault room10.1016/S0168-9002(01)00234-0 ↗
4. Characterisation of the secondary neutron field generated by a compact PET cyclotron with MCNP6 and experimental measurements10.1016/j.apradiso.2017.07.031 ↗
5. Jakubowska, T., Długosz-Lisiecka, M., and Biegała, M. (2023). Comparison of radionuclide impurities activated during irradiation of 18O enriched water in tantalum and silver targets during the production of 18F in a cyclotron. Molecules, 28.10.3390/molecules28083485 ↗
6. Radioactive by-products of a self-shielded cyclotron and the liquid target system for F-18 routine production10.1007/s13246-016-0426-1 ↗
7. Radiation Protection Studies for Medical Particle Accelerators using Fluka Monte Carlo Code10.1093/rpd/ncw302 ↗
8. Evaluation of stray neutron distribution in medical cyclotron vault room by neutron activation analysis approach10.1007/s10967-009-7461-2 ↗
9. Development of a radiation hardness testing facility for semiconductor devices at a medical cyclotron10.1016/S0168-9002(96)00831-5 ↗
10. Measurement of thick target neutron yield from the reaction (p + 181Ta) with projectiles in the range of 6–20 MeV10.1016/j.nima.2017.10.046 ↗
11. Use of the MCNPX to calculate the neutron spectra around the GE-PETtrace 8 cyclotron of the CDTN/CNEN, Brazil10.1016/j.apradiso.2013.07.022 ↗
12. Orchard, G.M., Feuerstake, T., McDonald, C., and Waker, A.J. (2021). Investigation of the stray neutron fields produced from proton irradiated Ta, Co-59, Ni, Fe, Inconel X750 and stainless steel 310 targets in a materials testing laboratory environment. Appl. Radiat. Isot., 178.10.1016/j.apradiso.2021.109961 ↗
13. Microdosimetric understanding of neutron RBE using a tissue-equivalent proportional counter
14. Neutron radiobiology and dosimetry10.1667/RADE-20-00213.1 ↗
15. A microdosimetric analysis of the interactions of mono-energetic neutrons with human tissue10.1016/j.ejmp.2020.04.001 ↗
16. ICRU (1993). Stopping Powers and Ranges for Protons and Alpha Particles, J ICRU. ICRU Report 49.
17. Neutron relative biological effectiveness in Hiroshima and Nagasaki atomic bomb survivors: A critical review10.1093/jrr/rrw079 ↗
18. Gene expression-based biodosimetry for radiological incidents: assessment of dose and time after radiation exposure
19. Solid cancer incidence in atomic bomb survivors10.1667/RR0763.1 ↗
20. Predicting neutron RBE: Results from the ANDANTE project
21. ICRP Publication 26 (1977). Recommendations of the International Commission on Radiological Protection. Ann. ICRP, 1.
22. ICRP Publication 103 (2007). The 2007 Recommendations of the International Commission on Radiological Protection. Ann. ICRP, 37.
23. ICRP Publication 92 (2003). Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (wR). Ann. ICRP, 33.10.1016/S0146-6453(03)00024-1 ↗
24. NCRP (2009). Ionizing Radiation Exposure of the Population of the United States, National Council on Radiation Protection and Measurements. NCRP Report No. 160.
25. Accurate Monte Carlo modeling of cyclotrons for optimization of shielding and activation calculations10.1016/j.radphyschem.2015.01.001 ↗
26. Neutron spectra around medical cyclotrons
27. Radiation risk of ovarian cancer in atomic bomb survivors: 1958–2009
28. Levels of exposure to ionizing radiation among the personnel engaged in cyclotron operation and the personnel engaged in the production of radiopharmaceuticals, based on radiation monitoring system10.1093/rpd/ncaa012 ↗